BIOGEN INC. BIIB

Latest FY: 2025 Healthcare Drug Manufacturers - General
Market Price $209.75
Market Cap $31.11B
P/E Ratio 23.86
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑2.2% YoY
$9.89B
3-Yr CAGR: -0.9%
Net Income ↓-20.8% YoY
$1.29B
Net Margin: 13.1%
Free Cash Flow ↓-24.7% YoY
$2.05B
FCF Yield: 6.59%
EPS (Diluted) ↓-21.4% YoY
$8.79
Basic: $8.83
Return on Equity Efficiency
8.7%
ROA: 14.4%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (BIIB)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $11,448.8M $9,970.1M $3,702.8M $16.93 $4,522.4M $3,906.3M
FY 2017 $12,273.9M +7.2% $10,643.9M $2,539.1M -31.4% $11.92 -29.6% $4,551.0M $3,683.6M -5.7%
FY 2018 $13,452.9M +9.6% $11,636.6M $4,430.7M +74.5% $21.58 +81.0% $6,187.7M $5,417.1M +47.1%
FY 2019 $14,377.9M +6.9% $12,422.5M $5,888.5M +32.9% $31.42 +45.6% $7,078.6M $6,564.1M +21.2%
FY 2020 $13,444.6M -6.5% $11,639.4M $4,000.6M -32.1% $24.80 -21.1% $4,229.8M $3,805.0M -42.0%
FY 2021 $10,981.7M -18.3% $8,872.0M $1,556.1M -61.1% $10.40 -58.1% $3,639.9M $3,381.8M -11.1%
FY 2022 $10,173.4M -7.4% $7,895.1M $3,046.9M +95.8% $20.87 +100.7% $1,384.3M $1,144.0M -66.2%
FY 2023 $9,835.6M -3.3% $7,302.2M $1,161.1M -61.9% $7.97 -61.8% $1,547.2M $1,270.2M +11.0%
FY 2024 $9,675.9M -1.6% $7,365.5M $1,632.2M +40.6% $11.18 +40.3% $2,875.5M $2,721.8M +114.3%
FY 2025 $9,890.6M +2.2% $7,486.4M $1,292.9M -20.8% $8.79 -21.4% $2,204.6M $2,050.8M -24.7%
$

Valuation

Market Price $209.75
Market Cap $31.11B
Enterprise Value $34.48B
P/E Ratio 23.86
P/B Ratio 2.09
FCF Yield 6.59%
Dividend Yield N/A
Shares Outstanding 147,637,100
%

Profitability & Margins

Gross Margin 75.69%
Operating Margin 0.25%
Net Margin 13.07%
Return on Equity (ROE) 8.74%
Return on Assets (ROA) 14.41%
Asset Turnover 1.10x
Revenue 3-Yr CAGR -0.94%
🛡️

Financial Health & Liquidity

Current Ratio 2.68
Cash Ratio 0.87
Debt / Equity 0.425
Debt / Assets 0.701
Cash & Equivalents $2.91B
Total Debt $6.29B
Book Value / Share $100.24
💧

Cash Flow Efficiency

Operating Cash Flow $2.20B
Capital Expenditures (CapEx) $153.80M
Free Cash Flow $2.05B
OCF / Revenue 22.29%
FCF / Revenue 20.73%
FCF 3-Yr CAGR 21.48%
🏷️

Per Share Metrics

EPS (Diluted) $8.79
EPS (Basic) $8.83
Dividends / Share N/A
Book Value / Share $100.24
EPS YoY Growth -21.38%
🏛️

Balance Sheet (FY 2025)

Total Assets $8.97B
Total Liabilities $3.35B
Stockholders' Equity $14.80B
Current Assets $8.97B
Current Liabilities $3.35B